Skip to content

Big Pharma

Public Pharma For Europe, A Game-Changer For Access To Medicines

“It’s time to step up, promote health justice, and meet the real needs of people,” says Alan Silva from the European chapter of the People’s Health Movement (PHM), addressing the need for revolutionizing pharma policies in Europe. A long-time advocate for access to medicines, Silva understands how important it is for Europe to change the way it thinks about research and development, but also production and distribution of health technologies. If the region were able to de-link itself from the interests of transnational pharmaceutical companies, it would be a true game changer, he says. “We need public pharma in Europe so we can stop relying on health solutions driven by profit,” he says.

The Final Nail In Psychiatry’s Antidepressant Coffin

Historically, there have always been some patients who report that any treatment for depression—including bloodletting—has worked for them, but science demands that for a treatment to be deemed truly effective, it must work better than a placebo or the passage of time without any treatment. This is especially important for antidepressant drugs—including Prozac, Zoloft, and other selective serotonin reuptake inhibitors (SSRIs), as well as Effexor, Cymbalta, and other serotonin and norepinephrine reuptake inhibitors (SNRIs)—because all of these drugs have uncontroversial troubling side effects.

Health Activists Reveal Big Pharma’s Covid-19 Vaccine Heist In South Africa

In August this year, a coalition of civil society organizations in South Africa, which includes the Health Justice Initiative (HJI) and the Public Service Accountability Monitor (PSAM), achieved a remarkable breakthrough in the discussion surrounding COVID-19 vaccines. This milestone was reached after the Pretoria High Court issued an order instructing the Department of Health to disclose the contracts and proceedings of meetings pertaining to the procurement of COVID-19 vaccine doses from Pfizer, Janssen, the Serum Institute of India, and the public-private global health partnership Gavi.

This Is How We Challenge The Power Of Big Pharma

People in the United States pay the highest prices for pharmaceuticals, and Big Pharma spends hundreds of millions of dollars every year for lobbying to keep it that way. The United States is also experiencing a growing shortage of medications from antibiotics to cancer treatments and more despite being a wealthy country. Clearing the FOG speaks with Dana Brown of the Democracy Collaborative to understand what is behind the high prices and shortages. She also describes solutions to these crises and how states across the country are taking action to directly confront the stranglehold the pharmaceutical industry has over our lives.

Big Pharma’s American Con

In response to this week’s launch of a new program letting Medicare negotiate lower prices for a handful of medicines, drugmakers are insisting the initiative will limit patients’ access to medicine and stifle the development of new cures. However, all 10 of the drugs up for negotiation are already being sold in other countries at fractions of what pharmaceutical companies are charging for them in the United States, according to a Lever review — and drugmakers are reporting huge revenues from those foreign sales. In some cases, Americans — whose tax money subsidizes the development of virtually all medicines approved for sale in the U.S. — are being charged 1,000 percent more than foreign patients for the same drugs.

Drug Patents Are Stifling Progress And Making Us Sicker

The healthcare system in the U.S. shows time and time again that under capitalism, profit maximization trumps individual and societal well-being. We saw a recent example from Gilead Sciences manipulating patent laws to extend the life of one of their drugs and delay the release of another, potentially safer option. Gilead’s efforts serve as just one example of how under capitalism patent laws are used to maximize profits at the expense of public well-being. In the world of HIV/AIDS treatment and prevention, many of the more recent treatments center on using a combination of different drugs that target different parts of HIV’s replication cycle.

Public Pharma Is The Best Solution To The Problem Of Drug Shortages

Drug shortages in the United States are at a record high. At least 14 essential generic cancer drugs are currently in shortage, forcing patients and doctors to make difficult decisions to delay or ration first-line treatments, or accept second-best treatments. ADHD treatments, antibiotics, children’s acetaminophen, and many other critical medicines are also in short supply. But most of the solutions being discussed are just Band-Aids on a broken system. They would do nothing to transform the incentives that routinely produce shortages and other market failures. What we really need — for the health of our economy and society — is a robust public option in pharmaceuticals that produces and distributes essential medicines, such as cancer treatments.

Millions Of People In The US Ration Medicine

A new Centers for Disease Control and Prevention (CDC) report published this month reveals that approximately 9.2 million people in the US try to save money by rationing their medication. Most adults between the ages of 18 and 64 take at least one prescription medication, but 8% of them—9.2 million people—ration medicine by skipping doses, taking less than instructed, or delaying a refill. Meanwhile, pharmaceutical giants like Merck are fighting tooth and nail against President Biden’s limited checks on astronomical medication prices. Giving the government power to negotiate medicine prices with companies is “tantamount to extortion,” Merck argues in a recent lawsuit.

A Big Miss On Drug Prices

The Biden administration has seen firsthand in the past few weeks the benefits of using statutory power to bring down prescription drug costs. With Novo Nordisk and Sanofi following the lead of Eli Lilly and announcing their intent to slash the list price of their insulin medications by 65 percent or more, practically all diabetes patients will see relief, mostly thanks to a change in Medicaid rebates stuck into the American Rescue Plan. It upended the usual laissez-faire attitude about prescription price-gouging, and showed that the government, as a major medication buyer, can intervene to lower costs.

NHS Price Problem Is Big Pharma, Not Striking Nurses

Imagine a disability almost disappearing if you flew out of the Global South. I have severe haemophilia, a genetic condition that interferes with the body’s ability to clot after bleeding. When left untreated, anything — even a bruise or merely sitting down — can trigger a bleed, internally or externally. Anti-clotting injections can stop this. However, outside the advanced West, these injections are sold at exorbitantly high prices. When I was a child in India, my parents couldn’t afford such treatment, so they’d bury my bleeding joints under piles of ice to freeze them. Almost all the bleeds I experienced in India were left untreated, resulting in permanent damage to my joints and internal organs. In the U.K., the NHS home-delivers me these injections twice a month. This global medical apartheid is created and perpetuated by pharmaceutical monopolies.

Brazil: Pharma Companies Attempt To Overturn Supreme Court’s Historic Decision On Patents

The barriers that certain intellectual property rules can generate – preventing the fair distribution of vaccines and medicines – are a recurring theme in debates on global health. Traumatic experiences such as the HIV/AIDS treatment access crisis in the 90s, the global rationing of hepatitis C treatment in 2014, and the unfair distribution of COVID-19 vaccines are concrete examples of the right to health being systematically violated when monopolies over medical technologies are established and exercised arbitrarily. It is urgent to recognize, expose and confront the abuses that are committed in the patent system that result in death and suffering for millions of people. In Brazil, we are currently experiencing a situation of triple abuse, which threatens the populations’ access to dozens of essential medicines.

New Studies: Big Pharma Has Been Lying About Anti-Depressants For Years

So I know that I’m supposed to cover the Most Censored News and the fact that massive new studies show antidepressants don’t do nearly what we were told they do is on the cover of Newsweek does not exactly count as the most censored news. But I’ll get to the censored part in a minute. Newsweek reports, “In 2019, one in eight Americans—43 million in all—were taking a Selective Serotonin Reuptake Inhibitor (SSRI), and those numbers have likely risen among a public ridden with COVID-induced anxiety.” In fact, over the past few years, so many people were demanding Zoloft that the FDA warned there would be a shortage. Think about that, one in eight Americans are on antidepressants, and assuming almost all of those people are 18 or older, 43 million is actually one in every six American adults. That is insane.

Access To Medicines Summit Urges More Decisive Action Against Big Pharma

From July 19-21, activists from across the globe gathered in Istanbul for the second edition of the Global Summit on Intellectual Property and Access to Medicines (GSIPA2M). This event is a biennial gathering organized by the International Treatment Preparedness Coalition (ITPC) and Make Medicines Affordable consortium to hold critical debates and discussions on ensuring that intellectual property rights don’t undermine equitable access to lifesaving medicines. At the summit, one thing became crystal clear: the challenges of the Access to Medicines (A2M) movement are diverse and enormous. They include Big Pharma’s unstoppable greed and influence over governments, multi-stakeholder initiatives usurping the role of UN institutions, and insufficiency of national-level laws and institutions.

Medics For The People Has A Radical Plan To Rebuild Health Care

MPLP was established in 1971 by a group of physicians who were also members of the Workers’ Party of Belgium (PTB/PVDA). They did this because they felt the need to translate words to action, to ensure that healthcare is accessible to the people who need it, and this included a way of providing people free health consultations. They started the first health house in Antwerp, and since then, we have managed to establish 10 more health houses, guided by the same ideals from more than 50 years ago. There are many more health workers working with MPLP now, too, and not only physicians: nurses, psychologists, they’re all part of our teams now. But of course, during this time, a lot of things changed: the impact of social determinants of health developed in one way, the pharmaceutical industry changed a lot, and so on.

Global Actions Condemn Big Pharma’s Vaccine Profiteering

As major pharmaceutical executives and investors convened virtually on Thursday for their annual shareholder meetings, campaigners took to the streets in the U.S., the U.K., India, South Africa, and elsewhere to condemn major drug companies for hoarding technology and prioritizing profits over equitable distribution of coronavirus vaccines. Outside Pfizer's U.K. headquarters, activists dropped mock sacks of money and positioned wheelbarrows full of fake cash near the building's entrance to denounce the New York-based company's opposition to tech transfer initiatives and other efforts to expand coronavirus vaccine production in developing nations, where billions have been denied access to the shots. Pfizer has also faced backlash for obstructing African countries' attempts to study Paxlovid, the company's oral anti-viral treatment for Covid-19.
Sign Up To Our Daily Digest

Independent media outlets are being suppressed and dropped by corporations like Google, Facebook and Twitter. Sign up for our daily email digest before it’s too late so you don’t miss the latest movement news.